Evidence of depression affecting multimorbidity in survey data from the Brazilian population

Running: Evidence of depression affecting multimorbidity

Luis Fernando Silva Castro-de-Araujo. Center of Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil. Dept of Psychiatry, The University of Melbourne, Austin Health, Victoria, Australia. Idearaujo@unimelb.edu.au. Orcid: 0000-0002-0952-5052

Jacyra Azevedo Paiva de Araujo (corresponding author). Center of Data and Knowledge Integration for Health (CIDACS), Fiocruz, R. Mundo, 121. Salvador, Bahia, Brazil. jacyra.paiva@fiocruz.com. Orcid:0000-0002-8258-8244

Elisângela da Silva Rodrigues. Center of Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil. Address: R. Mundo, 121. Trobogy, Salvador, Bahia, Brazil. Federal University of Ceará, Campus Jardins de Anita, Itapajé, Ceará, Brazil. <u>elisangela.rodrigues@ufc.br</u>. 0000-0003-1207-5731

Rodrigo Lins Rodrigues. Center of Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil. Address: R. Mundo, 121. Trobogy, Salvador, Bahia, Brazil. Rural Federal University of Pernambuco, Department of Education (DED), Recife, Pernambuco, Brazil. <u>rodrigomuribec@gmail.com</u>. orcid.org/0000-0002-3598-5204.

Richard A Kanaan. Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia. Richard.kanaan@unimelb.edu.au. Orcid: 0000-0003-0992-1917

Evidence of depression affecting multimorbidity

Abstract

Objectives: Depression is associated with multimorbidity, the occurrence of two or more chronic diseases. Although the effect of multimorbidity on depression is relatively well known, the opposite effect is less well studied. We aimed to examine the effect of depression on multimorbidity using data from a nationally representative Brazilian survey. **Methods:** We used information from all respondents above 15 years of age of the Brazilian National Survey on Access, Use, and Promotion of the Rational Use of Medicines (PNAUM) from 2014. A structural equation model was fit to the data with a specification that included the relationship between depressive syndrome and multimorbidity, controlled by age and body mass index. **Results:** The data set comprised 28,382 subjects. The model presented fit the data well, and revealed a statistically significant, positive, moderate-size effect (0.355) of depression on multimorbidity. **Conclusion:** Depression appears to make a moderate contribution to the development of multimorbidity.

Keywords: multimorbidity, depression, structural equation modeling

Introduction

Depression is one of the leading health concerns worldwide today^{1,2}. Over 350 million people are affected by this disorder and prevalence in the general population is estimated between 3 to 10%¹. It is the single largest cause of years lost to disability², as it is a chronic disorder with symptoms that last for long periods and are recurring. It is also related to worse quality of life, medical morbidity and higher mortality³.

There is evidence that depression is associated with multimorbidity, the occurrence of two or more chronic diseases. It has been shown that the direction of this association seems to run from multimorbidity to depression^{4,5}. As individuals age, they tend to become alone, losing friends and family members, which renders them susceptible to depressive symptoms⁶. Furthermore, with age they are subject to brain vascular injury due to hypertension, diabetes mellitus, obesity, and high blood cholesterol⁷. Examining the relation between multimorbidity and depression is important as a global health preventive measure, as it can help match resources to the individuals who are hit the hardest in crises like the recent Covid19 pandemic. For example, during the COVID19 pandemic, multimorbidity was associated with increased anxiety and depressive symptoms both during the social isolation phase ⁸ and post-infection⁹. A systematic review published by Read et al. (2017) reported that people with multimorbidity have twice the risk of depressive disorders⁷. Socioeconomic factors seem to play an important role in the multimorbidity of mental disorders and chronic diseases, as this combination of disorders are more common in more deprived areas, where they particularly affect younger individuals^{10,11}.

Multimorbidity is known to increase with age, reaching higher prevalence in very old individuals. There is an ongoing effort of trying to identify patterns of clustering for these conditions, which varies significantly across studies¹². A three-cluster pattern seems to be emerging, with musculoskeletal, cardiometabolic, and neuropsychiatric clusters^{4,12}. Furthermore, being overweight is associated with multimorbidity in a dose-response pattern. A recent Finnish study reported a hazard ratio of 2.83 for obesity and 2.67 for those overweight¹³ in developing multimorbidity. It is therefore essential to take ageing and body mass index (BMI) into consideration in every multimorbidity study.

By contrast, the effect of depression on multimorbidity is seldom investigated. Subjects with depression are vulnerable to multimorbidity due to poor lifestyle choices (such as tobacco smoking or taking less exercise), limited adherence to clinical treatment and poor access to health¹⁴. There is also evidence that depression and multimorbidity have common biological and psychosocial drivers (inflamation, stress, economic burden) that might interact and result in one or both conditions¹⁸. Additionally, some medications for depression are associated with metabolic syndromes, obesity, and cardiovascular events^{15–17}. So, though it is clear that multimorbidity has an important effect on depression, there is a potential causal path in the opposite direction. This paper aims to investigate this, the effect of depression on multimorbidity, using a publicly available Brazilian survey including 28,382 respondents from 2014, and incorporating age and BMI as controls, in a structural equation model that accounts for error measurement.

Methods

Data source

Data from the National Survey on Access, Use, and Promotion of the Rational Use of Medicines in Brazil (PNAUM) were used in this study. The interviews for this survey took place between September 2013 and February 2014¹⁴, and were carried out by 165 trained interviewers. Only permanent residents of urban areas of Brazil were interviewed. All respondents in the available set were included in our analysis, which ranged from 15 to 99 years. Data were downloaded from the PNAUM website (http://www.ufrgs.br/pnaum/documentos/micro-dados/microdadosadultos/view) and pre-processed by RLR to allow analysis in the R statistical environment. The PNAUM data collection was described previously ¹⁹. The data is public domain and is freely available from the website, along with raking weights for each respondent. The raking was performed according to the population distribution obtained in the 2013 Brazilian National Survey on Health by age, gender and region. The 2013 Brazilian National Survey (PNS 2013) is a Survey carried out by the Brazilian Institute of Geography and Statistics to evaluate the performance of the National Health System in terms of access and use of available services, as well as the surveillance of the chronic non-communicable diseases and related risk factors (https://www.ibge.gov.br/estatisticas/sociais/saude/29540-2013-pesquisa-nacional-desaude.html?=&t=microdados).

Variables

The included variables were: age; body mass index (BMI); age when respondent was diagnosed with depression; psychiatric medication use, whether the respondent was using any psychiatric medication at the time of the interview; number of medications for chronic clinical diseases; cumulative number of chronic clinical diseases; multimorbidity, whether the patient had multimorbidity or not coded as 0/1 and included in the model as continuous; time medicated, time in years since beginning to use medications for chronic clinical conditions. In the SEM specification, the variables for depression severity, psychiatric medication use, and time since depression diagnosis were used to specify a reflective latent variable representing depression syndrome. The chronic-disease related variables were used to specify a reflective latent variable representing multimorbidity. One particular question was not standard and was

not validated in previous studies, the depression severity question. The interviewers asked "how much limitation was due to the respondent diagnosis of depression", without specifying the type of limitation. It was coded on a likert scale (1, no limitations; 2, mildly; 3, moderately;4, severe;5, very severe). In the pre-processing of this data, knowing the limitations of the statistical package we used, we re-coded this variable so that respondents that did not have depression would be coded as zero.

Data analysis

All analyses were performed using R version 4.1.3 (<u>https://cran.r-project.org/</u>). All analyses used an alpha of 0.05. The overall missingness of the entire dataset was below 10% (Supplemental material). Missing data were filled by pooling from 5 multiply-imputed data frames using the R mice package with the classification and regression trees algorithm²⁰. The analytic strategy used structural equation modelling, allowing both investigation of latent constructs and accounting for measurement error. The structural equation model specification can be seen in Figure 1. The estimation of the coefficients was performed using the lavaan survey package version 1.1.3.1 and incorporated the rake weights. This package does not allow categorical variables. This is the reason all variables were included in the model as continuous. For complex survey data, i.e. with weights, there currently is no alternative to this limitation. Identification was automatically tested by loading the model specification into the umx package²¹ and using the mxCheckIdentification tool²². The model is locally identified. The path diagram of figure 1 was built using Onyx²³. The estimation was maximum likelihood based, using the "MLM" option to obtain robust fit statistics.

[Figure 1]

Results

After pre-processing, the set contained 28,382 respondents. Demographic and clinical statistics are shown in Table 1. Continuous variables were analysed with the average of the descriptive

measures, median, minimum, maximum and standard deviation (SD) and categorical variables were described with the total number of observations and their corresponding percentages stratified by sex. The data set consisted of 8,780 (30.9%) males and 19,602 (69.1%) females. The individuals had a mean age of 61.04 (SD 14.04) years, and most patients were aged between 60 and 99 years (Males: 60.4% and Females: 52.7%). Both males and females had on average 2 chronic diseases (Males: 2.05 (SD 1.30) and Females: 2.30 (SD 1.38)). This was also observed in the number of medications for chronic disease treatment (Males: 2.10 (SD 1.28) and Females: 2.30 (SD 1.32)). Most individuals resided in the South (Males: 25.3% and Females: 25.0%) and Southeast regions (Males: 23.8% and Females: 23.6%), while individuals from the North of the country were the minority in this data set (Men: 14.9% and Women : 12.9%). Of those responding, 64.8% were considered multimorbid, 59.6% of males and 67.2% of females. Only 0.8% of respondents used psychiatric medication, 0.4% of males and 1.1% of females. Females engaged in intense physical exercise on average 7.06 (SD 22.25) days per week, while males exercised on average 4.62 (SD 10.26) days per week. Males smoked on average 17.30 (SD 18.44) cigarettes per day and females 15.11 (SD 17.36) cigarettes per day. On average, individuals with depression were diagnosed at 48.48 (SD 21.02) years of age. males at age 52.12 (SD 19.74), and females at age 47.76 (SD 21.19). In response to the depression severity variable, the majority of individuals did not endorse any life limitations from depression (Males: 4.3% and Females: 8.4%) others acknowledged few limitations (Males: 3.0% and Females: 7.2%), moderate limitations (Males: 1.7% and Females: 4.1%), intense limitations (Males: 1.1% and Females: 2.9%) and very intense limitations (Males: 0.7% and Females: 1.6%). Note that this variable also encoded subjects who did not have a diagnosed depression, which was the majority of both sexes (Table 1).

[Table 1]

The path of interest for the SEM was the regression between the latent variable representing depression to the latent variable representing multimorbidity. The model fit was good: $\chi^2(23) = 671.442$, p < 0.001; Robust CFI = 0.971; Robust TLI = 0.955; Robust RMSEA = 0.051 (90%CI 0.048,0.055); Robust SRMR = 0.026. All observed variables were modelled with error measurement variances (Figure 1). The standardized coefficient found for this path was 0.355 and was statistically significant (p<0.05), which means that for each SD increase in the depression syndrome latent variable, an increase of 0.35 SD in multimorbidity is expected. This effect is medium size. Age contributed a positivemoderate effect on multimorbidity, and BMI

contributed a small positive effect on multimorbidity, though neither were statistically significant). The upper part of the model (BMI and age) was specified so that these variables could act as controls in the relationship between depression and multimorbidity.

Age and BMI both had significant small negative effects on the depressive syndrome latent variable. The former was surprising, given that depression is positively associated with ageing²⁴.

Discussion

This is a cross-sectional, maximum likelihood based analysis of the association between depression and multimorbidity using complex survey data from Brazilian individuals. It found a significant association in the direction of depression affecting multimorbidity, a direction seldom studied in the multimorbidity literature. The size of the effect found (0.355) was medium, and the model presented a good fit in several fit indices.

Most of the present literature in multimorbidity has focused on the effect of multimorbidity in depression. We have shown that the effect of depression on multimorbidity is of importance. In our analysis, age had a moderate effect on multimorbidity (0.332) and BMI had a small effect on (0.06, not significant) multimorbidity. The former confirms the pattern found in the literature ¹², the latter was less than what was expected based on what had been reported of the effect of BMI on multimorbidity ¹³. In this analysis, BMI and age had little effect on depressive syndrome, which was surprising give that data comprises older subjects and the known relationship between age and depression ²⁵.

Obesity (measured by BMI or waist circumference) is a highly prevalent health condition associated with early death and high health $costs^{26}$. The rising incidence of obesity in the lowmiddle income countries is associated with multimorbidity. Romano et al. (2021) reported based on a sample of elderly (over 60 years) individuals that obesity (BMI \geq 30 kg/m2) was associated with 1.43 times higher odds for multimorbidity. The relation was significantly positive between obesity and hypertension, arthritis, asthma, diabetes and chronic back pain²⁷. In another study from Finland using participants from the UK, researchers found that individuals with obesity started presenting complex multimorbidity by age 55, whereas individuals with healthy weight would only show multimorbidity by age 75. Also, they found that the degree of obesity was associated with complex multimorbidity in a dose-response relationship¹³.

The co-occurrence of depression and multimorbidity has been described by numerous previous studies^{18,28}. Zhang et al. (2022) found that multimorbidity was associated with increased odds of having depressive symptoms (adjusted odds ratio of 1.51), and developing depressive symptoms (adjusted odds ratio of 1.65). Depression worsens the outcomes of people living with multimorbidity increasing disability, accelerating cognitive decay and also increasing costs in older individuals^{5,7,29}. Moreover, depression was associated with a higher incidence of somatic disease, cardiometabolic disease, musculoskeletal diseases and digestive diseases in a 6-year follow-up cohort in the Netherlands³⁰. Momen et al. (2020) conducted a cohort study using 16 years of health data in Denmark and found that individuals with a mood disorder had a cumulative incidence within 15 years after the diagnosis of a mental disorder for circulatory conditions of 40.9% (95% Cl, 40.5 to 41.3). Another study using the Center for Epidemiological Studies Depression Scale (CES-D) found a positive association between depression score and chronic disease incidence. Every one point symptom increase in the CES-D scale resulted in a 5% increase in incidence of chronic diseases³¹. Given the prevalence of depression, the public health implications of this are substantial.

The study findings should be interpreted in the context of some limitations. We used the term 'effects' throughout the paper, as is the standard in SEM analyses, but it was a cross-sectional study, and therefore should not be considered a causal investigation. In the survey used in the study, the diagnosis of depression was self-reported, and no diagnostic instrument was used. The negative coefficients from age and BMI to depression may be related to the continuous treatment of some variables that are categorical or ordinal, which might have interfered in the variances for the latent variable representing depression. Despite these limitations, SEM allowed us to model measurement error, which is expected in survey data. This is often overlooked in psychiatry research and is an important shortcoming in survey data of psychiatric outcomes. Also, the fit indices suggest that the chosen model was parsimonious.

Conclusion

We have presented here evidence of the effect of depression on multimorbidity in a large, nationwide representative data set. Several mechanisms can explain the effect in this direction. Subjects with depression might adhere less to clinical treatments, engage less in healthy life style, exercise less often, or anti-depressant use may increase multimorbidity by its metabolic

effects. However, this can only be confirmed in studies with longitudinal designs. A future direction in this field could be to investigate whether the effect of depression on multimorbidity is bidirectional, which can be assessed in quasi-experimental methods such as cross-lagged panel data models.

Individual contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Elisângela da Silva Rodrigues and Rodrigo Lins Rodrigues. The first draft of the manuscript was written by Jacyra Paiva de Araujo and Luis Castro-de-Araujo. Richard AA Kanaan contributed to later versions of the manuscript. All authors commented on versions of the manuscript, read and approved the final manuscript.

Conflicts of interest

Authors report no conflicts of interest

Acknowledgments

LFSCA, ESR, and JAPA were funded by the Medical Research Council - UK, Grant no. MR/T03355X/1 during the study.

References

1 Marcus M, Yasamy MT, Ommeren M, Chisholm D, Saxena S. Depression: A global public health concern. World Health Organ Pap Depress. 2012:6–8.

2Smith K. Mental health: A world of depression. Nature. 2014;515:180-1.

3Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–38.

- 4Castro-de-Araujo LFS, Cortes F, Teixeira de Siqueira N, Rodrigues E, Machado DB, Araujo JAP de, et al. Patterns of multimorbidity and some psychiatric disorders: A systematic review of the literature. Front Psychol. 2022:29.
- 5 de Araujo JAP, Xavier ÉFM, Rodrigues E da S, Machado DB, Barreto ME, Kanaan RA, et al. Main and moderated effects of multimorbidity and depressive symptoms on cognition. Braz J Psychiatry. 2022.
- 6Cámara C de la, Saz P, López-Antón R, Ventura T, Día JL, Lobo A. Depression in the elderly community: II. Outcome in a 4.5 years follow-up. Eur J Psychiatry. 2008;22:141–50.
- 7Read JR, Sharpe L, Modini M, Dear BF. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36–46.
- 8Castro-de-Araujo LFS, da Silva Rodrigues E, Machado DB, Henriques CMP, Verotti MP, Gonçalves AQ, et al. Multimorbidity worsened anxiety and depression symptoms during the COVID-19 pandemic in Brazil. J Affect Disord. 2022.
- 9Azevedo MN, Rodrigues E da S, Passos EAFV, Filho MAB, Barreto APA, Lima MCC, et al. Multimorbidity associated with anxiety symptomatology in post-COVID patients. Psychiatry Res. 2022;309:114427.
- 10 Taylor AW, Price K, Gill TK, Adams R, Pilkington R, Carrangis N, et al. Multimorbidity not just an older person's issue. Results from an Australian biomedical study. BMC Public Health. 2010;10:718.
- 11 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380:37–43.
- 12 Ermogenous C, Green C, Jackson T, Ferguson M, Lord JM. Treating age-related multimorbidity: the drug discovery challenge. Drug Discov Today. 2020;25:1403–15.
- 13 Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10:253–63.
- 14 Patel V, Chatterji S. Integrating Mental Health In Care For Noncommunicable Diseases: An Imperative For Person-Centered Care. Health Aff Proj Hope. 2015;34:1498–505.

15 Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer

Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020;34:1133–47.

- 16 Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015;37:46–8.
- 17 Serretti A, Mandelli L, M L, elli. Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis. J Clin Psychiatry. 2010;71:979.
- 18 Triolo F, Harber-Aschan L, Belvederi Murri M, Calderón-Larrañaga A, Vetrano DL, Sjöberg L, et al. The complex interplay between depression and multimorbidity in late life: risks and pathways. Mech Ageing Dev. 2020;192:111383.
- 19 Mengue SS, Bertoldi AD, Boing AC, Tavares NUL, Pizzol T da SD, Oliveira MA, et al. National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM): household survey component methods. Rev Saúde Pública. 2016;50.
- 20 Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45:1–67.
- 21 Bates TC, Maes H, Neale MC. umx: Twin and Path-Based Structural Equation Modeling in R. Twin Res Hum Genet. 2019;22:27–41.
- Hunter MD, Garrison SM, Burt SA, Rodgers JL. The Analytic Identification of Variance Component Models Common to Behavior Genetics. Behav Genet. 2021;51:425–37.
- von Oertzen T, Brandmaier AM, Tsang S. Structural Equation Modeling With Ωnyx. Struct Equ Model Multidiscip J. 2015;22:148–61.
- 24 Blazer DG. Depression in Late Life: Review and Commentary. J Gerontol Ser A. 2003;58:M249–65.
- 25 Castro-de-Araujo LFS, Barcelos-Ferreira R, Martins CB, Bottino CMC. Depressive Morbidity among elderly individuals who are hospitalized, reside at long-term care facilities, and are under outpatient care in Brazil: a meta-analysis. Rev Bras Psiquiatr. 2013;35:201–7.
- 26 Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.
- Romano E, Ma R, Vancampfort D, Firth J, Felez-Nobrega M, Haro JM, et al.
 Multimorbidity and obesity in older adults from six low- and middle-income countries. Prev
 Med. 2021;153:106816.
- Zhang L, Shooshtari S, John PS, Menec VH. Multimorbidity and depressive symptoms in older adults and the role of social support: Evidence using Canadian Longitudinal Study on Aging (CLSA) data. PLOS ONE. 2022;17:e0276279.

- Fiske A, Wetherell JL, Gatz M. Depression in Older Adults. Annu Rev Clin Psychol. 2009;5:363–89.
- 30 Gaspersz R, Lamers F, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH. The Impact of Depressive Disorder Symptoms and Subtypes on 6-Year Incidence of Somatic Diseases. Psychother Psychosom. 2018;87:308–10.
- Poole L, Steptoe A. Depressive symptoms predict incident chronic disease burden
 10 pears later: Findings from the English Longitudinal Study of Ageing (ELSA). J Psychosom Res. 2018;113:30–6.

Table 1

Clinical and demographic data stratified by sex. Group comparison was performed using Chi-2 contingency table tests for the categorical variables and ANOVA for the continuous variables.

Male

Female

р

n	28382	8780 (30.9)	19602 (69.1)	
BMI (mean (SD))	27.22 (7.62)	27.10 (11.22)	27.27 (5.27)	0.079
Number of chronic conditions (mean (SD))	2.22 (1.36)	2.05 (1.30)	2.30 (1.38)	<0.001
Multimorbidity = Yes (%)	18396 (64.8)	5229 (59.6)	13167 (67.2)	<0.001
Number of medications used for chronic conditions (mean (SD))	2.24 (1.31)	2.10 (1.28)	2.30 (1.32)	<0.001
Region (%)				<0.001
North	3838 (13.5)	1310 (14.9)	2528 (12.9)	
Northeast	5889 (20.7)	1577 (18.0)	4312 (22.0)	
Southeast	6711 (23.6)	2093 (23.8)	4618 (23.6)	
South	7119 (25.1)	2220 (25.3)	4899 (25.0)	
Central-West	4825 (17.0)	1580 (18.0)	3245 (16.6)	
Psychiatric medication use = Yes (%)	241 (0.8)	34 (0.4)	207 (1.1)	<0.001
Time using medication for chronic conditions (mean (SD))	6.79 (7.42)	6.83 (7.55)	6.78 (7.36)	0.629
Age group (%)				<0.001
[15,32]	968 (3.4)	199 (2.3)	769 (3.9)	
(32,46]	3420 (12.0)	816 (9.3)	2604 (13.3)	
(46,60]	8367 (29.5)	2463 (28.1)	5904 (30.1)	
(60,99]	15627 (55.1)	5302 (60.4)	10325 (52.7)	
Age of depression diagnosis (mean (SD))	48.48 (21.02)	52.12 (19.74)	47.76 (21.19)	<0.001
Depression severity (%)				<0.001

Healthy (no depression dx)	22677 (79.9)	7837 (89.3)	14840 (75.7)
Does not causes burden	2032 (7.2)	376 (4.3)	1656 (8.4)
A little	1669 (5.9)	261 (3.0)	1408 (7.2)
Moderately	958 (3.4)	146 (1.7)	812 (4.1)
Intensely	672 (2.4)	100 (1.1)	572 (2.9)
Very intensely	374 (1.3)	60 (0.7)	314 (1.6)

BMI, body mass index.

Figure 1



SEM path specification. Dashed lines are negative coefficients. Standard SEM representation is used, circles are latent variables, boxes are measured variables. Standardized estimates. Model Fit: $\chi^2(23) = 671.442$, p < 0.001; Robust CFI = 0.971;Robust TLI = 0.955; Robust RMSEA = 0.051 (90%Cl0.048,0.055); Robust SRMR = 0.026. *, statistically significant. Age_dep, age in which the respondent was diagnosed with depression; Psy_med_use, whether the respondent used psychiatric medications; Severity, variable coding whether the respondent had depression and if yew, the burden it produced in their lives (no, mild, severe, very severe); n_med_chr, number of medications used to treat chronic conditions; n_chr_condition, number of chronic conditions; multimorbidity, whether the respondent endorsed multimorbidity; time_medicated, for how long the respondent has been using medications

Supplementary Material

Distribution of age by sex



Missing and categories and distribution in one picture

Missings, categories and distributions

Survey weights in structural equation modeling (SEM) with imputed data



Fit the model using weighted data (lavaan.survey.fit)

```
lavaan 0.6-11 ended normally after 98 iterations
```

Estimator	ML	
Optimization method	NLMINB	
Number of model parameters	31	
Number of observations	28382	

Model Test User Model:

	Standard	Robust
Test Statistic	1776.845	671.442
Degrees of freedom	23	23
P-value (Chi-square)	0.000	0.000
Scaling correction factor		2.646
Satorra-Bentler correction		
Model Test Baseline Model:		
Test statistic	78404.100	22657.464
Degrees of freedom	36	36
P-value	0.000	0.000
Scaling correction factor		3.460
User Model versus Baseline Model:		
Comparative Fit Index (CFI)	0.978	0.971
Tucker-Lewis Index (TLI)	0.965	0.955
Robust Comparative Fit Index (CFI) Robust Tucker-Lewis Index (TLI)		0.978 0.966
Loglikelihood and Information Criteria:		
Loglikelihood user model (H0)	-549910.090	-549910.090
Loglikelihood unrestricted model (H1)	-549021.668	-549021.668
Akaike (AIC)	1099882.180	1099882.180
Bayesian (BIC)	1100138.039	1100138.039
Sample-size adjusted Bayesian (BIC)	1100039.521	1100039.521

Root Mean Square Error of Approximation:

RMSEA				0.052	0.0	32	
90 Percent confid	lence inte	rval - lo	wer	0.050	0.0	30	
90 Percent confid	lence inte	rval - up	per	0.054	0.0	33	
P-value RMSEA <=	0.05			0.068	1.0	00	
Robust RMSEA					0.0	51	
90 Percent confid	lence inte	rval - lo	wer		0.0	48	
90 Percent confid	lence inte	rval - up	per		0.0	55	
Standardized Root M	lean Squar	e Residua	1:				
SRMR				0.026	0.0	26	
Parameter Estimates	5:						
Standard errors			Ro	bust.sem			
Information				Expected			
Information satur	rated (h1)	model	St	ructured			
Latent Variables:							
	Estimate	Std.Err	z-value	P(> z)	Std.lv	Std.all	
morbidity =~							
quant_med_cron	0.860	0.010	86.043	0.000	0.979	0.766	
quant_doe_cron	1.161	0.010	116.600	0.000	1.321	0.966	
multimorbidade	0.330	0.002	139.723	0.000	0.376	0.780	
tempo s mdcmnt			7 200	0 000	0 510	0 071	
	0.456	0.063	7.280	0.000	0.519	0.071	
dep =~	0.456	0.063	7.280	0.000	0.319	0.072	
dep =~ depressn_svrty	0.456	0.063	58.926	0.000	0.933	0.872	
dep =~ depressn_svrty medic_psi	0.456 0.933 0.019	0.063 0.016 0.002	7.280 58.926 9.340	0.000 0.000 0.000	0.933	0.872	

Regressions:							
	Estimate	Std.Err	z-value	P(> z)	Std.lv	Std.all	
morbidity ~							
idade	0.024	0.001	31.827	0.000	0.021	0.330	
imc	0.006	0.004	1.486	0.137	0.005	0.065	
dep	0.404	0.011	37.963	0.000	0.355	0.355	
dep ~							
idade	-0.002	0.001	-3.036	0.002	-0.002	-0.033	
imc	-0.001	0.000	-2.208	0.027	-0.001	-0.010	
Covariances:							
	Estimate	Std.Err	z-value	P(> z)	Std.lv	Std.all	
idade ~~							
imc	-15.045	4.690	-3.208	0.001	-15.045	-0.074	
Intercepts:							
	Estimate	Std.Err	z-value	P(> z)	Std.lv	Std.all	
.quant_med_cron	0.885	0.104	8.500	0.000	0.885	0.692	
.quant_doe_cron	0.412	0.139	2.969	0.003	0.412	0.302	
.multimorbidade	0.131	0.040	3.288	0.001	0.131	0.273	
.tempo_s_mdcmnt	6.145	0.126	48.878	0.000	6.145	0.837	
.depressn_svrty	0.605	0.041	14.577	0.000	0.605	0.565	
.medic_psi	0.013	0.001	9.994	0.000	0.013	0.128	
.age_depression	12.597	0.801	15.727	0.000	12.597	0.588	
idade	58.270	0.155	375.310	0.000	58.270	3.798	
imc	27.627	0.172	160.879	0.000	27.627	2.081	
.morbidity	0.000				0.000	0.000	
.dep	0.000				0.000	0.000	
Variances:							
	Estimate	Std.Err	z-value	P(> z)	Std.lv	Std.all	
.morbidity	1.000				0.772	0.772	

.dep	1.000				0.999	0.999
idade	235.350	3.504	67.167	0.000	235.350	1.000
imc	176.177	111.421	1.581	0.114	176.177	1.000
.quant_med_cron	0.675	0.012	54.268	0.000	0.675	0.413
.quant_doe_cron	0.123	0.013	9.457	0.000	0.123	0.066
.multimorbidade	0.091	0.001	79.826	0.000	0.091	0.391
.tempo_s_mdcmnt	53.685	1.893	28.359	0.000	53.685	0.995
.depressn_svrty	0.274	0.020	13.408	0.000	0.274	0.239
.medic_psi	0.009	0.001	11.540	0.000	0.009	0.962
.age_depression	128.985	7.887	16.353	0.000	128.985	0.281